New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 19, 2019 - The FDA announced the approval of SAGE Therapeutics’ Zulresso (brexanolone), for the treatment of postpartum depression (PPD) in adults.
Download PDF
Return to publications
